HRP20201684T1 - Tri-segmentirani arenavirusi kao vektori cjepiva - Google Patents
Tri-segmentirani arenavirusi kao vektori cjepiva Download PDFInfo
- Publication number
- HRP20201684T1 HRP20201684T1 HRP20201684TT HRP20201684T HRP20201684T1 HR P20201684 T1 HRP20201684 T1 HR P20201684T1 HR P20201684T T HRP20201684T T HR P20201684TT HR P20201684 T HRP20201684 T HR P20201684T HR P20201684 T1 HRP20201684 T1 HR P20201684T1
- Authority
- HR
- Croatia
- Prior art keywords
- arenavirus
- tri
- utr
- segment
- segmented
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10041—Use of virus, viral particle or viral elements as a vector
- C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10061—Methods of inactivation or attenuation
- C12N2760/10062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/80—Vectors comprising a special translation-regulating system from vertebrates
- C12N2840/85—Vectors comprising a special translation-regulating system from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462079493P | 2014-11-13 | 2014-11-13 | |
| PCT/EP2015/076458 WO2016075250A1 (en) | 2014-11-13 | 2015-11-12 | Tri-segmented arenaviruses as vaccine vectors |
| EP15794900.9A EP3218504B1 (en) | 2014-11-13 | 2015-11-12 | Tri-segmented arenaviruses as vaccine vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201684T1 true HRP20201684T1 (hr) | 2020-12-25 |
Family
ID=54545130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201684TT HRP20201684T1 (hr) | 2014-11-13 | 2015-11-12 | Tri-segmentirani arenavirusi kao vektori cjepiva |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10722564B2 (enExample) |
| EP (2) | EP3778903A1 (enExample) |
| JP (4) | JP6805139B2 (enExample) |
| CN (1) | CN107223130A (enExample) |
| AU (3) | AU2015345080B2 (enExample) |
| CA (1) | CA2967720C (enExample) |
| CY (1) | CY1123339T1 (enExample) |
| DK (1) | DK3218504T3 (enExample) |
| ES (1) | ES2811093T3 (enExample) |
| HR (1) | HRP20201684T1 (enExample) |
| HU (1) | HUE051390T2 (enExample) |
| LT (1) | LT3218504T (enExample) |
| PL (1) | PL3218504T3 (enExample) |
| PT (1) | PT3218504T (enExample) |
| RS (1) | RS60937B1 (enExample) |
| SI (1) | SI3218504T1 (enExample) |
| WO (1) | WO2016075250A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4186978A1 (en) | 2007-12-27 | 2023-05-31 | Universität Zürich | Replication-defective arenavirus vectors |
| HRP20211015T1 (hr) * | 2013-12-03 | 2021-10-01 | Hookipa Biotech Gmbh | Cjepivo protiv citomegalovirusa (cmv) |
| US10722564B2 (en) | 2014-11-13 | 2020-07-28 | Université de Genéve | Tri-segmented arenaviruses as vaccine vectors |
| CN107921117B (zh) | 2015-06-10 | 2022-06-07 | 霍欧奇帕生物科技有限公司 | Hpv疫苗 |
| WO2018045029A1 (en) * | 2016-09-02 | 2018-03-08 | The United States Of America, As Represented By The Secretary Of The Army | Pan south american arenavirus live attenuated vaccine |
| US11214598B2 (en) * | 2015-11-04 | 2022-01-04 | Hookipa Biotech Gmbh | Vaccines against hepatitis B virus |
| EP3960197A1 (en) * | 2015-11-12 | 2022-03-02 | Hookipa Biotech GmbH | Arenavirus particles as cancer vaccines |
| CA3039356A1 (en) | 2016-11-04 | 2018-05-11 | Hookipa Biotech Gmbh | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines |
| CN110719788A (zh) * | 2017-04-07 | 2020-01-21 | 霍欧奇帕生物科技有限公司 | 治疗实体瘤的沙粒病毒颗粒 |
| EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
| CN108611310A (zh) * | 2018-04-28 | 2018-10-02 | 中国药科大学 | 一种重组Hsp65与STEAP1186-193融合蛋白的基因工程菌的构建 |
| CN108977434A (zh) * | 2018-07-03 | 2018-12-11 | 张罗 | 鼻腔脱落细胞rna的提取方法 |
| WO2020255023A1 (en) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof |
| EP3999107A1 (en) | 2019-07-16 | 2022-05-25 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| EP4458975A3 (en) | 2019-09-30 | 2025-02-12 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
| EP4055173A1 (en) * | 2019-11-07 | 2022-09-14 | Universität Basel Vizerektorat Forschung | Arenaviruses as vectors |
| EP4157342A1 (en) | 2020-05-29 | 2023-04-05 | Hookipa Biotech GmbH | Cancer treatment strategies using arenavirus vectors |
| US12053517B2 (en) | 2021-01-14 | 2024-08-06 | Gilead Sciences, Inc. | HIV vaccines and methods of using |
| WO2022159664A1 (en) * | 2021-01-22 | 2022-07-28 | Chan Zuckerberg Biohub, Inc. | Engineered multi-segmented rna viruses for large-scale combinatorial genetic screening |
| BR112023019365A2 (pt) | 2021-03-23 | 2023-12-26 | Hookipa Biotech Gmbh | Segmento s de arenavírus, cdna, vetor de expressão de dna, célula hospedeira, partícula de arenavírus trissegmentada, método para gerar uma partícula de arenavírus trissegmentada, composição farmacêutica, método para tratar câncer de próstata e kit |
| WO2022238546A1 (en) | 2021-05-13 | 2022-11-17 | Hookipa Biotech Gmbh | Arenaviruses as vectors |
| EP4429698A1 (en) | 2021-11-08 | 2024-09-18 | Hookipa Biotech GmbH | Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies |
| CN114231562A (zh) * | 2021-12-15 | 2022-03-25 | 中国科学院武汉病毒研究所 | 一种表达荧光素酶基因的淋巴脉络丛脑膜炎病毒及其构建方法和应用 |
| WO2023152116A1 (en) | 2022-02-08 | 2023-08-17 | Hookipa Biotech Gmbh | Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines |
| CN119677546A (zh) | 2022-07-12 | 2025-03-21 | 吉利德科学公司 | Hiv免疫原性多肽和疫苗及其用途 |
| WO2025056782A1 (en) | 2023-09-15 | 2025-03-20 | Hookipa Biotech Gmbh | Arenavirus formulations, methods and uses thereof |
| WO2025191169A1 (en) | 2024-03-15 | 2025-09-18 | Hookipa Biotech Gmbh | Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US8158413B2 (en) * | 2005-10-17 | 2012-04-17 | Institut Pasteur | Lentiviral vector-based vaccine |
| EP2007765B1 (en) | 2006-03-23 | 2012-06-27 | Novartis AG | Immunopotentiating compounds |
| CA2646539A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| EP4186978A1 (en) * | 2007-12-27 | 2023-05-31 | Universität Zürich | Replication-defective arenavirus vectors |
| GB201001726D0 (en) * | 2010-02-03 | 2010-03-24 | Univ St Andrews | Bunyavirus vaccine |
| WO2012162428A1 (en) | 2011-05-23 | 2012-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prime-boost vaccination for viral infection |
| EP3269387B1 (en) | 2012-01-24 | 2019-07-17 | Sanford Health | Polynucleotides and polypeptides for treating oncogenic viral polypeptide positive tumors |
| EP2968506B1 (en) | 2013-03-15 | 2019-07-31 | Université de Genève | Anti-mycobacterial vaccines |
| GB201305361D0 (en) | 2013-03-25 | 2013-05-08 | Univ Edinburgh | Enhanced expression |
| HRP20211015T1 (hr) | 2013-12-03 | 2021-10-01 | Hookipa Biotech Gmbh | Cjepivo protiv citomegalovirusa (cmv) |
| WO2015183895A1 (en) | 2014-05-27 | 2015-12-03 | University Of Rochester | Novel arenavirus vaccine |
| US9943585B2 (en) | 2014-07-30 | 2018-04-17 | University Of Rochester | Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV) |
| AU2015321557B2 (en) * | 2014-09-22 | 2020-05-14 | Regents Of The University Of Minnesota | Pichinde virus reverse genetics system and methods of use |
| GB201419572D0 (en) | 2014-11-03 | 2014-12-17 | Pirbright Inst The | Virus |
| US10722564B2 (en) | 2014-11-13 | 2020-07-28 | Université de Genéve | Tri-segmented arenaviruses as vaccine vectors |
| DE102015207036A1 (de) | 2015-04-17 | 2016-10-20 | Karl Sebastian Lang | Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften |
| CN107921117B (zh) | 2015-06-10 | 2022-06-07 | 霍欧奇帕生物科技有限公司 | Hpv疫苗 |
| US10849969B2 (en) | 2015-10-23 | 2020-12-01 | Institut Pasteur | Recombinant attenuated Mopeia virus comprising a modified nucleoprotein with reduced exonuclease activity |
| US11214598B2 (en) | 2015-11-04 | 2022-01-04 | Hookipa Biotech Gmbh | Vaccines against hepatitis B virus |
| EP3960197A1 (en) | 2015-11-12 | 2022-03-02 | Hookipa Biotech GmbH | Arenavirus particles as cancer vaccines |
| CN117486979A (zh) | 2016-05-18 | 2024-02-02 | 巴塞尔大学 | 作为疫苗载体的三区段pichinde病毒 |
| CA3039356A1 (en) | 2016-11-04 | 2018-05-11 | Hookipa Biotech Gmbh | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines |
| CN110719788A (zh) | 2017-04-07 | 2020-01-21 | 霍欧奇帕生物科技有限公司 | 治疗实体瘤的沙粒病毒颗粒 |
-
2015
- 2015-11-12 US US15/526,211 patent/US10722564B2/en active Active
- 2015-11-12 DK DK15794900.9T patent/DK3218504T3/da active
- 2015-11-12 LT LTEP15794900.9T patent/LT3218504T/lt unknown
- 2015-11-12 AU AU2015345080A patent/AU2015345080B2/en active Active
- 2015-11-12 PT PT157949009T patent/PT3218504T/pt unknown
- 2015-11-12 EP EP20184468.5A patent/EP3778903A1/en active Pending
- 2015-11-12 CA CA2967720A patent/CA2967720C/en active Active
- 2015-11-12 PL PL15794900T patent/PL3218504T3/pl unknown
- 2015-11-12 SI SI201531397T patent/SI3218504T1/sl unknown
- 2015-11-12 JP JP2017525893A patent/JP6805139B2/ja active Active
- 2015-11-12 ES ES15794900T patent/ES2811093T3/es active Active
- 2015-11-12 RS RS20201251A patent/RS60937B1/sr unknown
- 2015-11-12 CN CN201580073235.6A patent/CN107223130A/zh active Pending
- 2015-11-12 WO PCT/EP2015/076458 patent/WO2016075250A1/en not_active Ceased
- 2015-11-12 HR HRP20201684TT patent/HRP20201684T1/hr unknown
- 2015-11-12 HU HUE15794900A patent/HUE051390T2/hu unknown
- 2015-11-12 EP EP15794900.9A patent/EP3218504B1/en active Active
-
2020
- 2020-07-07 US US16/922,489 patent/US20210145950A1/en not_active Abandoned
- 2020-09-16 CY CY20201100879T patent/CY1123339T1/el unknown
- 2020-12-03 JP JP2020201083A patent/JP2021045154A/ja active Pending
-
2022
- 2022-01-06 AU AU2022200061A patent/AU2022200061A1/en not_active Abandoned
-
2023
- 2023-01-05 JP JP2023000345A patent/JP2023036933A/ja active Pending
- 2023-11-13 US US18/507,584 patent/US20240082376A1/en active Pending
-
2024
- 2024-11-06 AU AU2024259760A patent/AU2024259760A1/en active Pending
-
2025
- 2025-08-21 JP JP2025138430A patent/JP2025170342A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021045154A (ja) | 2021-03-25 |
| US20210145950A1 (en) | 2021-05-20 |
| HK1244034A1 (en) | 2018-07-27 |
| SI3218504T1 (sl) | 2020-11-30 |
| ES2811093T3 (es) | 2021-03-10 |
| CA2967720C (en) | 2024-01-02 |
| US20240082376A1 (en) | 2024-03-14 |
| US20170319673A1 (en) | 2017-11-09 |
| EP3218504B1 (en) | 2020-07-22 |
| JP2017535267A (ja) | 2017-11-30 |
| DK3218504T3 (da) | 2020-10-19 |
| CN107223130A (zh) | 2017-09-29 |
| RS60937B1 (sr) | 2020-11-30 |
| AU2015345080A1 (en) | 2017-06-01 |
| WO2016075250A1 (en) | 2016-05-19 |
| PT3218504T (pt) | 2020-09-24 |
| AU2022200061A1 (en) | 2022-02-03 |
| CA2967720A1 (en) | 2016-05-19 |
| JP2025170342A (ja) | 2025-11-18 |
| LT3218504T (lt) | 2020-09-10 |
| EP3218504A1 (en) | 2017-09-20 |
| CY1123339T1 (el) | 2021-12-31 |
| JP2023036933A (ja) | 2023-03-14 |
| EP3778903A1 (en) | 2021-02-17 |
| US10722564B2 (en) | 2020-07-28 |
| AU2024259760A1 (en) | 2024-11-28 |
| HUE051390T2 (hu) | 2021-03-01 |
| PL3218504T3 (pl) | 2021-02-08 |
| AU2015345080B2 (en) | 2022-01-27 |
| JP6805139B2 (ja) | 2020-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201684T1 (hr) | Tri-segmentirani arenavirusi kao vektori cjepiva | |
| JP2017535267A5 (enExample) | ||
| HRP20211015T1 (hr) | Cjepivo protiv citomegalovirusa (cmv) | |
| HRP20221474T1 (hr) | Cjepiva protiv virusa hepatitisa b | |
| FI2604695T3 (fi) | Replikaatiokyvyttömiä arenavirusvektoreita | |
| JP2019516410A5 (enExample) | ||
| JP2011507536A5 (enExample) | ||
| Barber | Vesicular stomatitis virus as an oncolytic vector | |
| Hastie et al. | Understanding and altering cell tropism of vesicular stomatitis virus | |
| RS53257B2 (sr) | Lentiviralni vektori pseudotipizirani sa omotačem od glikobelančevine iz sindbis-virusa | |
| US8445270B2 (en) | Immortalized avian cell lines and use thereof | |
| JP2021182922A5 (enExample) | ||
| JP2007520214A5 (enExample) | ||
| JP2018186815A5 (enExample) | ||
| HRP20241379T1 (hr) | Cjepiva za hbv i postupci za liječenje hbv | |
| JP2017527557A5 (enExample) | ||
| WO2020076820A3 (en) | Compositions and methods for preparing viral vectors | |
| RU2018136481A (ru) | КОНСТРУИРОВАНИЕ ОБЛИГАТНОГО ВЕКТОРА НА ОСНОВЕ ОНКОЛИТИЧЕСКИХ ВИРУСОВ ПРОСТОГО ГЕРПЕСА (oHSV) И КОНСТРУКЦИИ ДЛЯ ТЕРАПИИ РАКА | |
| JP2018536433A5 (enExample) | ||
| JP2015527296A5 (enExample) | ||
| MX2015005505A (es) | Vacunas basadas en particular recombinantes contra la infeccion de citomegalovirus humano. | |
| HRP20231025T1 (hr) | Onkolitički virus vakcinije | |
| WO2010105251A3 (en) | Non-integrating retroviral vector vaccines | |
| JP2013517773A5 (enExample) | ||
| JP2016514957A5 (enExample) |